Sign Up to like & get
recommendations!
1
Published in 2022 at "Research in Pharmaceutical Sciences"
DOI: 10.4103/1735-5362.350243
Abstract: Background and purpose: The lack of a new effective treatment for small cell lung cancer (SCLC) is an unresolved problem. Due to the new identification of delta-like ligand 3 (DLL3) and its high expression in…
read more here.
Keywords:
rovalpituzumab antibody;
design two;
analysis;
structure ... See more keywords